Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: Exploratory indirect comparison based on metaanalysis of pivotal clinical trials

Croatian Medical Journal

Volumn 51, Issue 2, 2010, Pages 113-123

  Trkulja, Vladimir ^a   Kolundžic, Robert ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; ENOXAPARIN; RIVAROXABAN;

ARTICLE; ATTRIBUTABLE RISK; BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; GINGIVA BLEEDING; HEMATOMA; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; RECTUM HEMORRHAGE; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; WOUND HEMATOMA;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BENZIMIDAZOLES; ENOXAPARIN; HEMORRHAGE; HUMANS; MORPHOLINES; POSTOPERATIVE CARE; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAFETY; SURVIVAL ANALYSIS; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 77953735839     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: 10.3325/cmj.2010.51.113     Document Type: Article

References (24)

1. Samama CM, Ravaud P, Parent F, Barré J, Mertl P, Mismetti P. Epidemiology of venous thromboembolism after lower limb arthroplasty: the FOTO study. J Thromb Haemost. 2007;5:2360-7. Medline:17908282 doi:10.1111/j.1538- 7836.2007.02779.x (Pubitemid 350154344)
2. Rahme E, Dasgupta K, Burman M, Yin H, Bernatsky S, Berry G, et al. Postdischarge thromboprophylaxis and mortality risk after hip-or knee-replacement surgery. CMAJ. 2008;178:1545-54. Medline:18519902
3. Callaghan JJ, Dorr LD, Engh GA, Hanssen AD, Healy WL, Lachiewicz PF, et al. Prophylaxis for thromboembolic disease: recommendations from the American College of Chest Physicians- are they appropriate for orthopaedic surgery? J Arthroplasty. 2005;20:273-4. Medline:15809941 doi:10.1016/j.arth.2005.01.014 (Pubitemid 40460790)
4. Hull RD, Yusen RD, Bergqvist D. State-of-the-art review: Assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis. Clin Appl Thromb Hemost. 2009;15:377-88. Medline:19608549 doi:10.1177/1076029609338712
5. European Medicines Evaluation Agency. Committee for Human Medicines (CHMP). CHMP assessment report for Xarelto (IN: rivaroxaban). EMEA/543519/2008. Available from: http://www.ema.europa.eu/humandocs/PDFs/EPAR/xarelto/H-944-en6. pdf. Accessed: April 6, 2010.
6. European Medicines Evaluation Agency. Committee for Human Medicines (CHMP). CHMP assessment report for Pradaxa (IN: dabigatran etexilate). EMEA/174363/2008. Available from: http://www.ema.europa.eu/humandocs/Humans/ EPAR/pradaxa/pradaxa.htm. Accessed: April 6, 2010.
7. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765-75. Medline:18579811 doi:10.1056/NEJMoa0800374 (Pubitemid 351930851)
8. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372:31-9. Medline:18582928 doi:10.1016/S0140- 6736(08)60880-60886
9. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776-86. Medline:18579812 doi:10.1056/NEJMoa076016 (Pubitemid 351930852)
10. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373:1673-80. Medline:19411100 doi:10.1016/S0140-6736(09)60734-60740
11. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949-56. Medline:17869635 doi:10.1016/S0140-6736(07)61445-61447 (Pubitemid 47393577)
12. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178-85. Medline:17764540 doi:10.1111/j.1538- 7836.2007.02748.x (Pubitemid 47617868)
13. RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24:1-9. Medline:18534438 doi:10.1016/j.arth.2008.01.132
14. McCullagh L, Tilson L, Walsh C, Barry M. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting. Pharmacoeconomics. 2009;27:829-46. Medline:19803538 doi:10.2165/11313800-000000000-00000
15. Quinlan DJ, Eikelboom JW, Dahl OE, Eriksson BI, Sidhu PS, Hirsh J. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J Thromb Haemost. 2007;5:1438-43. Medline:17425687 doi:10.1111/j.1538- 7836.2007.02571.x (Pubitemid 46965372)
16. Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 2009;338:b1147. Medline:19346285 doi:10.1136/bmj.b1147
17. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, et al. Indirect comparisons of competing interventions. Health Technol Assess. 2005;9:1-134. Medline:16014203
18. A ltman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326:219. Medline:12543843 doi:10.1136/bmj.326.7382.219
19. Johnson & Johnson Pharmaceutical Research & Development. Advisory Committee briefing book. Rivaroxaban for the prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery. Available from: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/UCM138385.pdf Accessed: April 6, 2010.
20. Xu Q. Xarelto (Rivaroxaban). Cardiovascular and renal drugs Advisory Committee meting March 19 2009. Available from: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/UCM143660. pdf. Accessed: April 6, 2010.
21. European Medicines Evaluation Agency. Committee for Human Medicines (CHMP). Guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboemoblic risk. CPMP/EWP/707/98 Rev. corr 2007. Available from: http://www.ema.europa.eu/pdfs/ human/ewp/70798en-fin.pdf. Accessed: April 6, 2010.
22. Lie SA, Engesaeter LB, Havelin LI, Gjessing HK, Vollset SE. Mortality after total hip replacement: 0-10-year follow-up of 39,543 patients in the Norwegian Arthroplasty Register. Acta Orthop Scand. 2000;71:19-27. Medline:10743987
23. Lie SA, Engesaeter LB, Havelin LI, Furnes O, Vollset SE. Early postoperative mortality after 67,548 total hip replacements: causes of death and thromboprophylaxis in 68 hospitals in Norway from 1987 to 1999. Acta Orthop Scand. 2002;73:392-9. Medline:12358110
24. Merli G, Spyropoulos AC, Caprini JA. Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations. Ann Surg. 2009;250:219-28. Medline:19638915 doi:10.1097/SLA.0b013e3181ae6dbe